2024-09-30 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of products, including pharmaceuticals, medical devices, nutritionals, and diagnostics.

**1. Performance and Relative Strength:**

* **Cumulative Return:** ABT has a cumulative return of 102.29%, compared to the S&P 500 (VOO) with a return of 133.28%.
* **Performance Gap:** The current performance gap between ABT and VOO is -30.99%. This indicates that ABT has underperformed the S&P 500 over the period analyzed. The relative performance gap is 11.95%, suggesting that ABT's performance is in the lower 11.95% percentile compared to its historical range.

**2. Recent Price Trends:**

* **Closing Price:** 112.72
* **5-Day Moving Average:** 113.31
* **20-Day Moving Average:** 114.83
* **60-Day Moving Average:** 109.94

The recent price action suggests a slight downward trend, as the closing price is below the 5-day, 20-day, and 60-day moving averages.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 32.87. An RSI below 30 suggests that the stock may be oversold.
* **PPO (Percentage Price Oscillator):** -0.58. A negative PPO indicates that the stock is currently in a downtrend.
* **Delta_Previous_Relative_Divergence:** -4.24. This indicates a recent short-term decline in relative strength.
* **Expected Return:** 0.0%. This is the projected return on investment over the next five years based on current market conditions.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2023-08-03 | 0.79 | 9.98 B$ |
| 2024-07-31 | 0.79 | 9.98 B$ |

The most recent earnings report for Q2 2024 showed EPS of $0.74, which was slightly below analysts' estimates. Revenue of $10.38 billion was also below expectations.

**5. News and Recent Issues:**

* **Recent Market Outlook:**  Analysts at FINBOLD see ABT as a "potential opportunity" citing its strong dividend yield and consistent earnings growth as key factors. However, they also note that the company's revenue growth may be challenged in the near term due to the macroeconomic environment.
* **Analyst Opinions:** Most analysts have a "Hold" rating on ABT, with some expressing optimism about the company's long-term growth potential in areas like medical devices and diagnostics. 
* **Performance Highlights:** ABT's consistent dividend payouts and focus on innovation have been key factors in its performance. The company has a strong track record of developing and commercializing new products, which could drive future growth.

**6. Overall Analysis:**

ABT's performance has lagged the overall market in recent months. While technical indicators suggest the stock may be oversold, current earnings reports have not been particularly strong.  Despite this, the company's dividend yield and focus on innovation offer some potential for future growth. Investors should carefully monitor the company's performance and news related to its key product areas.

**7. Recommendation:**

Given the recent performance and uncertain market outlook, a cautious approach is recommended. Investors may want to wait for clearer signs of positive momentum in the company's earnings and overall market conditions before making a significant investment in ABT.
